First Trust Advisors
ABCL icon

First Trust Advisors’s AbCellera Biologics ABCL Stock Holding History

First Trust Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-80,628
Closed -$817K – 2348
2022
Q4 		$817K Buy
+80,628
New +$931K ﹤0.01% 2026

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors's ABCL Position: Q1 2023 in Review

First Trust Advisors sold out of AbCellera Biologics (ABCL) in Q1 2023, closing a stake of 80,628 shares — an estimated $817K sold.

First Trust Advisors first reported a position in ABCL in Q4 2022 and held it in 1 quarter. The position peaked at $817K in Q4 2022. 183 funds tracked by Wall St. Rank hold ABCL as of Q1 2023.

  • First Trust Advisors reported no remaining AbCellera Biologics position as of Q1 2023 after selling out during the quarter.
  • First Trust Advisors sold 80,628 AbCellera Biologics shares in Q1 2023, an estimated $817K.
  • First Trust Advisors first reported a position in AbCellera Biologics in Q4 2022 and held it in 1 quarter.
  • First Trust Advisors's AbCellera Biologics position peaked at $817K in Q4 2022.
  • 183 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2023.

Based on First Trust Advisors's 13F filing for Q1 2023, filed 15 May 2023.